Apotex and Emcure Pharmaceuticals' Heritage subsidiary agreed to pay a combined $49.1m to settle three longstanding US antitrust suits alleging the companies engaged in “widespread, long-running” conspiracies to “artificially inflate and manipulate prices, reduce competition and unreasonably restrain access to numerous generic prescription drugs.”
Apotex And Heritage Reach $50m Settlements For US Price-Fixing Claims
Two more generics manufacturers have settled claims with 50 US attorneys general that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.
More from Generics
More from Legal & IP
• By
The Health and Human Services Department's decision to eliminate the Richardson Waiver may be a blow for transparency, but will not completely eliminate scrutiny of regulations, experts said.
• By
President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.
• By
Health and Human Services Secretary Robert F. Kennedy Jr. is moving FDA Chief Counsel Robert Foster to a new senior position as Chief Counsel for Food, Research, and Drugs at HHS. Hilary Perkins will become FDA chief counsel.